Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CTX130 in relapsed or refractory T or B cell malignancies
NCT04502446Phase 1Terminated
- Sponsor
- CRISPR Therapeutics
- Start
- Jul 2020
- Primary completion
- Aug 2024
- Modality
- Gene Silencing, CRISPR-Cas9, CAR-T Cells
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of CTX130 in T-cell lymphoma and diffuse large B-cell lymphoma (DLBCL), sponsored by CRISPR Therapeutics. Primary endpoints: Incidence of adverse events at 28 days and Objective Response Rate at 60 months. Started Jul 2020; status: terminated.
02
Drugs
CTX130
03
Conditions
T-cell lymphomadiffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT04502446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04502446.